West Virginia University is partnering with a California biotech company to accelerate the discovery of new drug therapies for marketing.
WVU in Morgantown and GATC Health Corp. have teamed up to use the company’s artificial intelligence platform to speed the discovery and commercialization of new therapies.
The partnership will allow WVU researchers to simulate billions of biological interactions, enabling fast, accurate discovery of molecular targets, new drugs and testing at the earliest stages of development. GATC officials say its technology has already contributed to significant discoveries in addiction, brain cancer, diabetes and other diseases.
“This partnership highlights West Virginia University’s dedication to driving innovation and transforming lives through groundbreaking research,” Clay Marsh, physician, chancellor and executive dean for Health Sciences at WVU, said in a prepared statement. “By joining forces with GATC Health and utilizing their cutting edge AI technology, we are empowering our researchers to accelerate the path from academic discovery to life-changing therapies, ensuring WVU remains at the forefront of addressing crucial health care challenges and delivering meaningful outcomes that benefit patients in West Virginia and across the globe.”
Traditional drug discovery and development is notoriously risky, expensive and time-consuming, with a failure rate of nearly 90% during clinical trials. Using GATC’s AI platform in the critical stages of drug discovery is expected to make the process faster, more efficient and more likely to succeed.
Irvine, Calif-based GATC Health, which has formed GATC West Virginia, also has offices and labs at the West Virginia University Innovation Corp. center in Morgantown, a 1.1-million-square-foot building that formerly housed a Mylan Pharmaceuticals manufacturing plant. GATC West Virginia said it’s enhancing its AI-powered lab operations and hiring additional scientists this year at the center.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.